Amaro Therapeutics, Inc.
Preclinical-stage company developing oral small-molecule agonists of extra-oral bitter taste receptors (TAS2Rs) to treat metabolic dysfunction, chronic inflammation, and cellular senescence. The organization combines computational receptor modeling, tissue-specific activation assays, in vivo disease models, and lead optimization to advance TAS2R-targeted therapeutics with an emphasis on metabolic and age-related indications.
Industries
N/A
Products
Oral TAS2R1 small-molecule agonist (preclinical lead program)
Preclinical oral small-molecule agonist program targeting the human TAS2R1 receptor intended to modulate enteroendocrine signaling and suppress cellular senescence; advanced through lead optimization and chronic preclinical studies.
Oral TAS2R1 small-molecule agonist (preclinical lead program)
Preclinical oral small-molecule agonist program targeting the human TAS2R1 receptor intended to modulate enteroendocrine signaling and suppress cellular senescence; advanced through lead optimization and chronic preclinical studies.
Services
TAS2R-focused discovery platform
Integrated discovery platform combining computational receptor models, tissue-specific activation assays, and in vivo validation to identify and optimize small-molecule TAS2R agonists.
TAS2R-focused discovery platform
Integrated discovery platform combining computational receptor models, tissue-specific activation assays, and in vivo validation to identify and optimize small-molecule TAS2R agonists.
Expertise Areas
- Small-molecule drug discovery
- GPCR (TAS2R) pharmacology
- Metabolic disease therapeutics
- Cellular senescence and senomorphic approaches
Key Technologies
- GPCR-targeted small-molecule discovery
- Computational receptor modeling
- Artificial intelligence / in silico modeling
- Cell-based receptor activation assays